NIH R01 · 2025
PROJECT SUMMARY About 100,000 people die annually in the U.S. because of opioid overdose or complications of opioid use disorder (OUD). Three medications for OUD (MOUD) are FDA-approved and regularly used to treat OUD: methadone, buprenorphine, and extended-release naltrexone (XR-NTX). However, persons who use opioids, including those prescribed MOUDs, report sleep disruption. In addition to the sleep centers of the brain, mu opioid receptors (MORs) are also expressed in the retina (including the human retina), specifically in ganglion cells that are critically important for non-image forming photoreception including circadian regulation of sleep-wake behavior. Pre-clinical studies show…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.